[CAS NO. 1400591-39-0] Tosufloxacin tosylate hydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1400591-39-0]

Catalog

HY-B1802A

Brand

MCE

CAS

1400591-39-0

DESCRIPTION [1400591-39-0]

Overview

MDL	-
Molecular Weight	594.56
Molecular Formula	C26H25F3N4O7S
SMILES	CC1=CC=C(S(=O)(O)=O)C=C1.O=C(C2=CN(C3=CC=C(F)C=C3F)C4=C(C=C(F)C(N5CC(N)CC5)=N4)C2=O)O.O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic . Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria ^[1] ^[2] .

IC50 & Target

Quinolone

In Vitro

Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus , Staphylococcus epidermidis , streptococci , enterococci , Bacteroides fragilis , Clostridium difficile , and Clostridium perfringens ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	S. aureus , Staphylococcus epidermidis , streptococci , enterococci , Bacteroides fragilis , Clostridium difficile , and Clostridium perfringens
Concentration:	0.05-3.13 μg/mL
Incubation Time:	18 hours
Result:	Showed MIC ₉₀ s (MICs for 90% of the isolates tested) ranging from 0.05 to 1.56 μg/mL for S. aureus , Staphylococcus epidermidis , streptococci , and enterococci . Showed MIC ₉₀ s of 1.56, 3.13, and 0.20 μg/mL for Bacteroides fragilis , Clostridium difficile , and Clostridium perfringens , respectively.

In Vivo

Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus , E. coli , and P. aeruginosa in vivo ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc:ICR mice infected with S. aureus ^[2]
Dosage:	1.27-2.15 mg/kg
Administration:	Oral gavage; 1.27-2.15 mg/kg; once
Result:	Showed 50% effective dose (ED ₅₀ ) of 1.62 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with E. coli ^[2]
Dosage:	0.16-0.30 mg/kg
Administration:	Oral gavage; 0.16-0.30 mg/kg; once
Result:	Showed 50% effective dose (ED ₅₀ ) of 0.22 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with P. aeruginosa ^[2]
Dosage:	7.66-13.39 mg/kg
Administration:	Oral gavage; 7.66-13.39 mg/kg; once
Result:	Showed 50% effective dose (ED ₅₀ ) of 10.13 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.78 μg/mL.

Appearance

Solid

Source

Salmonella enteritidis

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 12.5 mg/mL ( 21.02 mM ; Need ultrasonic)

H ₂ O : 1 mg/mL ( 1.68 mM ; ultrasonic and warming and heat to 80°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6819 mL	8.4096 mL	16.8192 mL
5 mM	0.3364 mL	1.6819 mL	3.3638 mL
10 mM	0.1682 mL	0.8410 mL	1.6819 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 1.25 mg/mL (2.10 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, 4-methylbenzenesulfonate, hydrate (1:1:?)